Why the study?
Does olmesartan-based treatment improve clinic and home systolic blood pressure in patients with masked, white-coat, poorly controlled, and well-controlled hypertension?
Does olmesartan-based treatment improve clinic and home systolic blood pressure in patients with masked, white-coat, poorly controlled, and well-controlled hypertension?
In real-world practice, olmesartan-based treatment effectively lowers elevated clinic or home blood pressure without causing excessive decreases in patients with already normal blood pressure in those settings.
Olmesartan-based treatment was associated with selective BP reductions; hypothesis-generating for subtype-specific effects and requires randomized confirmation.
The authors examined the effects of olmesartan-based treatment on clinic systolic blood pressure (CSBP) and morning home systolic blood pressure (HSBP) in 21,340 patients with masked hypertension (MH), white-coat hypertension (WCH), poorly controlled hypertension (PCH), and well-controlled hypertension (CH) using data from the Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure (HONEST) study. MH, WCH, PCH, and CH were defined using CSBP 140 mm Hg and MHSBP 135 mm Hg as cutoff values at baseline. At 16 weeks, the MH, WCH, PCH, and CH groups had changes in CSBP by -1.0, -15.2, -23.1, and 1.8 mm Hg, and changes in morning HSBP by -12.5, 1.0, -20.3, and 2.0 mm Hg, respectively. In conclusion, in "real-world" clinical practice, olmesartan-based treatment decreased high morning HBP or CBP without excessive decreases in normal morning HBP or CBP according to patients' BP status.
No takes yet. Share an insight, caveat, or question.
Kario et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: